Biomarker study of patients with HER2-negative metastatic breast cancer receiving combination therapy with nivolumab, bevacizumab and paclitaxel as first-line treatment (WJOG9917BTR)

被引：2
|
作者：
Ozaki, Y.
Kitano, S.
Matsumoto, K.
Takahashi, M.
Mukohara, T.
Futamura, M.
Masuda, N.
Tsurutani, J.
Yoshimura, K.
Minami, H.
Takano, T.
机构：
[1] Toranomon Gen Hosp, Tokyo, Japan
[2] Natl Canc Ctr, Tokyo, Japan
[3] Hyogo Canc Ctr, Akashi, Hyogo, Japan
[4] NHO Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[5] Natl Canc Ctr Hosp East, Chiba, Japan
[6] Gifu Univ, Gifu, Japan
[7] NHO Osaka Natl Hosp, Osaka, Japan
[8] Kindai Univ, Osaka, Japan
[9] Kanazawa Univ Hosp, Kanazawa, Ishikawa, Japan
[10] Kobe Univ, Sch Med, Kobe, Hyogo, Japan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-OT1-12-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT1-12-02
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    Lobo, Christopher
    Lopes, Gilberto
    Baez, Odalys
    Castrellon, Aurelio
    Ferrell, Annapoorna
    Higgins, Connie
    Hurley, Erin
    Hurley, Judith
    Reis, Isildinha
    Richman, Stephen
    Seo, Pearl
    Silva, Orlando
    Slingerland, Joyce
    Tukia, Keleni
    Welsh, Catherine
    Glueck, Stefan
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (02) : 427 - 435
  • [22] Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
    Fabi, Alessandra
    Russillo, Michelangelo
    Ferretti, Gianluigi
    Metro, Giulio
    Nistico, Cecilia
    Papaldo, Paola
    De Vita, Ferdinando
    D'Auria, Giuliana
    Vidiri, Antonello
    Giannarelli, Diana
    Cognetti, Francesco
    BMC CANCER, 2012, 12
  • [23] Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    Christopher Lobo
    Gilberto Lopes
    Odalys Baez
    Aurelio Castrellon
    Annapoorna Ferrell
    Connie Higgins
    Erin Hurley
    Judith Hurley
    Isildinha Reis
    Stephen Richman
    Pearl Seo
    Orlando Silva
    Joyce Slingerland
    Keleni Tukia
    Catherine Welsh
    Stefan Glück
    Breast Cancer Research and Treatment, 2010, 123 : 427 - 435
  • [24] Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy
    Nakamoto, Shogo
    Watanabe, Junichiro
    Ohtani, Shoichiro
    Morita, Satoshi
    Ikeda, Masahiko
    IN VIVO, 2020, 34 (03): : 1377 - 1386
  • [25] A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer
    Gamucci, Teresa
    Mentuccia, Lucia
    Natoli, Clara
    Sperduti, Isabella
    Cassano, Alessandra
    Michelotti, Andrea
    Di Lauro, Luigi
    Sergi, Domenico
    Fabi, Alessandra
    Sarobba, Maria G.
    Marchetti, Paolo
    Barba, Maddalena
    Magnolfi, Emanuela
    Maugeri-Sacca, Marcello
    Rossi, Ernesto
    Sini, Valentina
    Grassadonia, Antonino
    Pellegrini, Domenica
    Astone, Antonino
    Nistico, Cecilia
    Angelini, Franco
    Vaccaro, Angela
    Pellegrino, Arianna
    De Angelis, Claudia
    Palleschi, Michela
    Moscetti, Luca
    Bertolini, Ilaria
    Buglioni, Simonetta
    Giordano, Antonio
    Pizzuti, Laura
    Vici, Patrizia
    JOURNAL OF CELLULAR PHYSIOLOGY, 2017, 232 (06) : 1571 - 1578
  • [26] INTERIM RESULTS OF A PHASE II STUDY OF NAB-PACLITAXEL, BEVACIZUMAB, AND GEMCITABINE AS FIRST-LINE THERAPY FOR PATIENTS WITH HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Gluck, S.
    Lobo, C.
    Hurley, J.
    Lopes, G.
    Reis, I.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    Tukia, K.
    ANNALS OF ONCOLOGY, 2008, 19 : 68 - 69
  • [27] First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
    Hardy-Bessard, Anne-Claire
    Brocard, Fabien
    Clatot, Florian
    Lortholary, Alain
    You, Benoit
    Grenier, Julien
    Martin-Babau, Jerome
    Lucas, Brigitte
    Meunier, Jerome
    Ferrero, Jean-Marc
    Savoye, Aude-Marie
    Marti, Adina
    Despax, Raymond
    Moullet, Isabelle
    Emile, George
    BREAST, 2020, 54 : 256 - 263
  • [28] Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons
    Sini, Valentina
    Cassano, Alessandra
    Corsi, Domenico
    De Laurentiis, Michele
    Gamucci, Teresa
    Mauri, Mariella
    Naso, Giuseppe
    Roselli, Mario
    Ruggeri, Enzo Maria
    Tonini, Giuseppe
    Vici, Patrizia
    Zampa, Germano
    Marchetti, Paolo
    TUMORI JOURNAL, 2016, 102 (05): : 472 - 480
  • [29] Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
    Christoph Zielinski
    Istvan Lang
    Semir Beslija
    Zsuzsanna Kahan
    Moshe J Inbar
    Salomon M Stemmer
    Rodica Anghel
    Damir Vrbanec
    Diethelm Messinger
    Thomas Brodowicz
    British Journal of Cancer, 2016, 114 : 163 - 170
  • [30] Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC).
    Masuda, N.
    Aogi, K.
    Ohno, S.
    Iwata, H.
    Kashiwaba, M.
    Fujiwara, Y.
    Ito, Y.
    Ueno, T.
    Saijo, N.
    Takashima, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345